Certara (NASDAQ:CERT) Updates FY 2025 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.450-0.470 for the period, compared to the consensus estimate of 0.370. The company issued revenue guidance of $415.0 million-$420.0 million, compared to the consensus revenue estimate of $421.7 million.

Certara Stock Performance

Shares of CERT traded down $2.30 during trading hours on Friday, reaching $8.97. 3,762,225 shares of the company’s stock traded hands, compared to its average volume of 1,713,865. Certara has a twelve month low of $8.64 and a twelve month high of $15.69. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of 177.68 and a beta of 1.44. The business’s fifty day simple moving average is $11.82 and its two-hundred day simple moving average is $11.55. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.16 and a quick ratio of 2.16.

Certara (NASDAQ:CERT) last issued its earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. Certara had a net margin of 1.97% and a return on equity of 5.11%. The firm had revenue of $104.62 million during the quarter, compared to analysts’ expectations of $104.53 million. During the same period last year, the firm posted $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. Analysts predict that Certara will post 0.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Craig Hallum assumed coverage on shares of Certara in a research report on Monday, September 29th. They issued a “buy” rating and a $16.00 price target for the company. UBS Group decreased their target price on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Barclays cut their price objective on Certara from $16.00 to $14.00 and set an “overweight” rating for the company in a report on Friday. Weiss Ratings reissued a “sell (d)” rating on shares of Certara in a research report on Wednesday, October 8th. Finally, KeyCorp raised their price target on Certara from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $15.38.

Insider Activity at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the transaction, the insider directly owned 73,979 shares in the company, valued at approximately $807,850.68. The trade was a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.33% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Norges Bank bought a new stake in shares of Certara in the second quarter valued at approximately $425,000. First Trust Advisors LP increased its position in Certara by 3,000.6% during the second quarter. First Trust Advisors LP now owns 394,924 shares of the company’s stock worth $4,621,000 after acquiring an additional 382,187 shares during the period. Treasurer of the State of North Carolina raised its stake in Certara by 2.9% during the 2nd quarter. Treasurer of the State of North Carolina now owns 56,628 shares of the company’s stock valued at $663,000 after purchasing an additional 1,597 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Certara in the 2nd quarter worth $3,798,000. Finally, Ameriprise Financial Inc. increased its holdings in shares of Certara by 27.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock worth $63,889,000 after purchasing an additional 1,165,064 shares during the period. 73.96% of the stock is owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.